Prime Medicine Late Wednesday Announces Pricing Of $175M Upsized Initial Public Offering Of 10,294,118 Shares At A Price Of $17/Share
Prime Medicine Late Wednesday Announces Pricing Of $175M Upsized Initial Public Offering Of 10,294,118 Shares At A Price Of $17/Share
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 19, 2022. The offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, or via email: prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at (866) 718-1649 or by e-mail to prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com.$Prime Medicine, Inc. (PRME.US)$, a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being offered by Prime Medicine. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prime Medicine, are expected to be $175.0 million. In addition, the underwriters have a 30-day option to purchase up to 1,544,117 additional shares of common stock at the initial public offering price less underwriting discounts and commissions.
$Prime Medicine, Inc. (PRME.US)$一家致力於提供一種新類的差異化一次性治療遺傳療法的生物技術公司，今天宣布其上市規模的 10,294,118 股普通股的定價，以每股 17.00 美元的價格向公眾提供。所有股份均由中醫藥提供。在扣除包銷折扣和佣金以及普和醫療應付的其他發行費用之前，該項發行的總收益預計為 1.75 億美元。此外，承銷商有 30 天的選擇權，以首次公開發行價格購買高達 1,544,117 股普通股的額外股票，減去承銷折扣和佣金。
The shares are expected to begin trading on the Nasdaq Global Market on October 20, 2022 under the ticker symbol "PRME." The offering is expected to close on October 24, 2022, subject to the satisfaction of customary closing conditions.
預計這些股票將於 2022 年 10 月 20 日在納斯達克全球市場開始交易，股票代碼為「PRME」。根據慣常結束條件的滿意度，該產品預計將於 2022 年 10 月 24 日結束。
J.P. Morgan, Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering.
摩根大通，高盛集團有限公司有限責任公司，摩根士丹利和富瑞擔任該發行的聯合圖書運行經理。
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 19, 2022. The offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, or via email: prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at (866) 718-1649 or by e-mail to prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com.
證券交易委員會於 2022 年 10 月 19 日宣佈有關這些證券的登記聲明生效。此次發行僅通過招股說明書進行。如有提供，與發行有關的最終招股說明書的副本可以從以下地址獲得：摩根大通證券有限責任公司，注意：博德里奇金融解決方案，1155 長島大道，紐約州埃奇伍德 11717 或致電 866-803-9204 或通過電子郵件 prospectus-eq_fi@jpmchase.com; 高盛 ＆Co。有限責任公司，注意：招股章程部，200，紐約州紐約市西街 10282，通過電話：（866）471-2526，或通過電子郵件：prospectus-ny@ny.email.gs.com; 摩根士丹利 ＆CO。有限責任公司，注意：招股章程部，180 瓦里克街，2 樓，紐約，紐約 10014，通過電話在（866）718-1649 或通過電子郵件 prospectus@morganstanley.com; 傑弗瑞有限責任公司，注意：股權集團招股說明書部，520 麥迪遜大道，紐約，紐約州 10022，通過電話致電 87827-1-7388 或通過電子郵件到 Prospectus_Department@Jefferies.com。
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.
本新聞稿並不構成要約出售或徵求購買這些證券的要約，在根據該州或司法管轄區的證券法進行註冊或資格之前，該等要約、招攬或出售將是非法的任何州或司法管轄區，也不會在任何州或司法管轄區的國家或司法管轄區出售這些證券。
譯文內容由第三人軟體翻譯。
